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Abstract: Tumor-infiltrating CD8+ T cells (TIL) are of the utmost importance in anti-tumor immunity.
CD103 defines tumor-resident memory T cells (TRM cells) associated with improved survival
and response to immune checkpoint blockade (ICB) across human tumors. Co-expression of
CD39 and CD103 marks tumor-specific TRM with enhanced cytolytic potential, suggesting that
CD39+CD103+ TRM could be a suitable biomarker for immunotherapy. However, little is known
about the transcriptional activity of TRM cells in situ. We analyzed CD39+CD103+ TRM cells sorted from
human high-grade endometrial cancers (n = 3) using mRNA sequencing. Cells remained untreated or
were incubated with PMA/ionomycin (activation), actinomycin D (a platinum-like chemotherapeutic
that inhibits transcription), or a combination of the two. Resting CD39+CD103+ TRM cells were
transcriptionally active and expressed a characteristic TRM signature. Activated CD39+CD103+ TRM
cells differentially expressed PLEK, TWNK, and FOS, and cytokine genes IFNG, TNF, IL2, CSF2
(GM-CSF), and IL21. Findings were confirmed using qPCR and cytokine production was validated
by flow cytometry of cytotoxic TIL. We studied transcript stability and found that PMA-responsive
genes and mitochondrial genes were particularly stable. In conclusion, CD39+CD103+ TRM cells are
transcriptionally active TRM cells with a polyfunctional, reactivation-responsive repertoire. Secondly,
we hypothesize that differential regulation of transcript stability potentiates rapid responses upon
TRM reactivation in tumors.
Keywords: tissue-resident memory cell; endometrial cancer; CD103; CD39; transcript stability;
cytokinesis; IL-21
1. Introduction
The influence of tumor-infiltrating lymphocytes (TIL) on cancer prognosis is widely recognized,
and TIL are studied in a wide variety of solid tumors. The composition of the immune infiltrate is
of the utmost importance, as the immune architecture mainly determines whether the balance tips
towards an anti-tumor or pro-tumor immune response [1]. CD103, the αE subunit of integrin αEβ7,
defines intra-epithelial resident memory T cells (TRM cells) with increased cytolytic potential, improved
immune synapse formation, and increased tumor antigen sensitivity [2–4]. CD8+ T cells upregulate
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CD103 upon combined TCR stimulation and TGF-β signaling [5–7]. Even though TGF-β production
is commonly attributed to dendritic cells and T regulatory cells, differentiated CD103+ TRM are also
capable of self-producing activated TGF-β1 to maintain CD103 expression on their cell surface [8].
CD103+ TRM are associated with prolonged survival in many solid tumors [4,6,9–13], including
endometrial cancer (EC). Endometrial tumors are stratified into risk groups based on histology,
grade, and FIGO stage, among others [14]. In addition, EC can be classified according to molecular
subtype: copy number low/p53 wild-type, copy number high/p53 mutant, polymerase E mutant
(POLE-mutant), and mismatch repair deficient (dMMR/MSI). POLE-mutant, dMMR, and p53-aberrant
tumors are typically high-grade tumors [15]. Particularly, POLE-mutant and dMMR tumors harbor
many neoantigens and are more infiltrated by immune cells, including CD103+ TRM [16–18]. CD103+
TRM, both in tumor and non-tumor tissue, are marked by expression of PDCD1, ITGAE, CXCR6, and
SPRY1 in lung cancer [19]. Tumor-resident CD103+ TRM expressed a unique genotype compared to
non-tumor CD103+ TRM, characterized by expression of ENTPD1 (CD39) [20]. Indeed, bystander, i.e.,
non-tumor specific T cells, lack CD39 expression [21]. CD39, also known as ectonucleoside triphosphate
diphosphohydrolase 1 (ENTPD1), catalyzes the phosphohydrolysis of extracellular ATP and ADP to
eventually synthesize immunosuppressive adenosine. CD39 is upregulated on activated T cells [22],
regulates T cell activation and polarization, and is considered an immunosuppressive marker associated
with T cell exhaustion [23,24]. CD39 has therefore been put forth as an immunoregulatory checkpoint
and a new therapeutic target in cancer [25]. A further specification of TRM cells in endometrial
cancer might therefore be relevant, as CD39 and CD103 co-expression identifies tumor-resident,
clonally expanded, tumor antigen-specific T cells with superior cytolytic capacity [19,20]. Moreover,
tumor-resident CD103+ TRM differentially express immune checkpoints such as CTLA4, TIM3, LAG3,
and TIGIT, indicating T cell exhaustion due to excess antigen stimulation [9,18,19,26]. In line with this,
CD103+ TRM are linked to response to immune checkpoint blockade (ICB) [27,28]. Thus, it can be
hypothesized that patients with both a sufficient number of TRM cells and a specific subtype of TRM
cells are likely to respond to immunotherapy/immune checkpoint blockade. However, little is known
about transcriptional activity of TRM cells in situ. We studied the transcriptional profile of high-grade
endometrial cancer CD39+CD103+ TRM cells in situ, after T cell activation, and after transcriptional
inhibition with actinomycin D in order to elucidate core elements necessary for successful T cell
reactivation. Moreover, we studied the immune profile of TIL in the context of pretreatment with
actinomycin D, a platinum-like chemotherapeutic. In this study we showed that resting CD39+CD103+
TRM cells were transcriptionally active and expressed a characteristic tissue-resident transcriptional
profile. Upon activation, TRM cells upregulated markers of T cell activation, cytolytic activity, and
cytokine production. Secondly, we studied transcript stability and found that PMA-responsive immune
genes and mitochondrial genes were particularly stable, which led us to hypothesize this differential
regulation of transcript stability potentiates rapid responses upon TRM reactivation in tumors.
2. Results
2.1. CD39+CD103+ TRM and CD8+ TIL are Transcriptionally Active in Situ
We analyzed the transcriptome of CD39+CD103+ TRM and a reference population of CD8+
TIL in high-grade endometrial cancer using mRNA sequencing (summarized in Figure 1A).
The reference population was randomly sorted from the CD3+CD8+ population of each of the
tumor digests, but for further information, the CD39/CD103 staining of these tumors were added
(Supplementary Figure S1A).
To compare transcriptional profiles in resting condition to the transcriptional profile upon
activation and transcriptional inhibition, samples were either not treated (untreated) or treated
with PMA/ionomycin (PMA), actinomycin D (ACT), or a combination of both. Actinomycin D is
a chemotherapeutic with some similarities to platinum-based chemotherapy and is therefore also
of interest in immune cells in endometrial cancer. cDNA concentrations were comparable between
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CD39+CD103+ TRM and CD8+ bulk cells (Figure 1B). However, there were distinct differences between
treatment conditions: the cDNA concentration increased upon activation with PMA/ionomycin
and diminished upon transcriptional inhibition by actinomycin D independently of PMA treatment
(TRM median 4.92 ng/µL/100 cells untreated, 0.70 ng/µL/100 cells actinomycin D, 9.44 ng/µL/100 cells
PMA, and 2.48 ng/µL/100 cells combination, respectively). Principal component analysis identified
actinomycin D treatment as the first component, explaining 47% of variance, and PMA/ionomycin as
the second with a variance of 8% (Figure 1C). Resting, untreated, CD39+CD103+ TRM cells robustly
transcribed characteristic CD8+ T cell markers such as CD3D, CD3E, CD3G, CD8A, CD8B and CD27
(Figure 1D). In addition, they expressed several checkpoints frequently found in TRM such as CTLA4,
TIGIT, LAG3, HAVCR2, and PDCD1. Expression of several other T cell-related genes in resting
CD39+CD103+ TRM varied: IFNG was uniformly expressed, but several TNF ligands, TNF receptors,
chemokines, and chemokine receptors were expressed in some, but not all patient samples. It was
noteworthy that TNF, TNFSF4, TNFSF8, and TNFSF9, all associated with T cell activation, were
barely transcribed at baseline, as were most cytokine-related genes. We observed a similar expression
pattern in CD8+ bulk TIL (Supplementary Figure S1D). These findings indicate that transcription in
CD39+CD103+ TRM cells is ongoing during in vitro culture, and these T cells have baseline transcript
expression despite their exhausted phenotype.
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Figure 5. Activated CD8+ T cells are polyfunctional T cells that are responsive to (re)activation. (A) t-
stochastic neighbor embedding plots of flow cytometry data of three endometrial tumor digests 
stained for CD3, CD8, IFN-γ, TNF-α, IL-2, and Zombie Aqua (live/dead stain). (B) Exemplary flow 
cytometry image of CD8+ T cells stained for CD3, CD8, IFN-γ, TNF-α, and IL-2. (C) Endometrial 
digests stained as described in (B) (n = 6). Percentages of untreated cells (blue) or cells activated by 4-
h incubation with PMA/ionomycin (red) that produce no, one, two, or three of the depicted cytokines. 
Bars depict the median. (D) Endometrial cancer digests (n = 7) stained for CD3, CD8, IFN-γ, TNF-α, 
IL-2, and Zombie Aqua; 4 of these digests were additionally stained for IL-13 and IL-21, and 3 digests 
for IL-10 and GM-CSF. Percentages of untreated CD8+ TIL and CD8+ TIL activated by 4-h incubation 
with PMA/ionomycin positive for either of the depicted cytokines. Bars depict the median. (E) 
Exemplary flow cytometry images of CD8+ TIL stimulated for 4 h with PMA/ionomycin as depicted 
in D. (F) Heatmap of a customized set of T cell markers of library size-normalized, log2-transformed 
counts of PMA/ionomycin- and PMA/ionomycin + actinomycin D-treated CD39+CD103+ TRM cells. 
Of PMA-treated TIL, 31.8% (median of 6 samples) produced IFN-γ, TNF-α, IL-2, or a 
combination of these (Figure 5B,C), whereas only 3.8% of untreated cells produced any cytokine. In 
fact, 21.8% of activated cytokine-producing TIL were polyfunctional and expressed two or three of 
the studied cytokines (Figure 5C). Our sequencing and qPCR data indicated that TRM and CD8+ TIL 
might have a more extensive cytokine repertoire that also includes IL-10, IL-13, IL-21, and GM-CSF. 
To validate this, we performed a flow cytometry experiment of PMA/ionomycin-activated and 
unstimulated CD8+ TIL from endometrial cancer digests including these markers plus IFN-γ, TNF-
α, and IL-2 as an internal control. Activated CD8+ TIL in endometrial cancer barely produced IL-13 
(1.06%), but they did produce GM-CSF (median 26.08%) and, to a lesser extent, IL-21 (median 8.79%) 
Figure 1. CD39+CD103+ TRM cells sorted from human endometrial tumors are transcriptionally active.
(A) Overview of experimental set-up. CD39+CD103+ TRM cells and CD8+ TIL were sorted from human
high-grade endometrial cancer digests (n = 3). Subsequently, cells remained untreated or were treated
for 4.5 h with actinomycin , or 4 h of PMA/i nomyin or pre incubation for 30 min with ac inomycin
D followed by 4 h PMA/ionomycin. (B) Concentration of cDNA (ng/µL/100 cells) of CD39+CD103+
TRM cells and CD8+ TIL per treatment group. The median concentration + 95% confidence interval is
depicted. (C) Principal component analysis of mRNA sequencing data of all TRM samples. The first
two principal components are depicted. Individual patient samples are identified by separate colors.
(D) Heatmap of a customized set of T cell markers of library size-normalized, log2-transformed counts
of untreated CD39+CD103+ TRM cells from three patients. The scale applies to all similar heatmaps of
CD39+C 103+ TRM cells throughout the pap r.
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2.2. Transcription Inhibition by Actinomycin D Reveals Distinct Differences in Transcript Stability
We studied transcript turnover and transcript stability in CD39+CD103+ TRM cells and CD8+ TIL
by comparing untreated and transcriptionally halted samples treated with actinomycin D. We observed
a strong decrease in the number of transcripts in both CD39+CD103+ TRM and CD8+ TIL. This was
also reflected in the distribution of the volcano plots, with a distinctly larger negative fold change-tail
(Figure 2A, Supplementary Figure S1B, Supplementary Table S1, and Supplementary Table S2).
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Figure 2. Effect of actinomycin D on transcriptional activity of CD39+CD103+ TRM. (A) Volcano plot 
depicting differentially expressed genes (DEseq2) of CD39+CD103+ TRM cells treated with actinomycin 
D for 4.5 h versus untreated. Each dot represents a gene with a Benjamini–Hochberg adjusted p-value 
< 0.05. Differentially decreased genes are depicted as unstable, differentially increased genes as stable. 
Figure 2. Effect of actinomycin D on transcriptional activity of CD39+CD103+ TRM. (A) Volcano plot
depicting differentially expressed genes (DEseq2) of CD39+CD103+ TRM cells treated with actinomycin
D for 4.5 h versus untreated. Each dot represents a gene with a Benjamini–Hochberg adjusted p-value
< 0.05. Differentially decreased e es are depicted as unstable, differentially increased genes as
stable. (B) Gene ontology analysis of top-250 differentially stable genes performed by Panther DB.
(C) Fold changes of a customized set of T cell markers upon actinomycin D treatment versus untreated
CD39+CD103+ TRM and CD8+ TIL. (D) Co-functionality network of the top-250 differentially expressed
genes in actinomycin D versus untreated CD39+CD103+ TRM cells with default parameters. Several
Biocarta pathways with z-score >2 are annotated. (E) Median gene expression values of CD39+CD103+
TRM cells (log10 n+1), with the median value of untreated cells on the x-axis and of actinomycin D
samples on the y-axis. Significant differentially expressed genes (DESeq2) are depicted for untreated
(blue) and actinomycin D (orange) cells.
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In actinomycin D-treated samples, 3839 genes were differentially lower expressed compared to
untreated TRM. Top differentially expressed unstable genes in actinomycin D-treated versus untreated
cells included RPN2 (ribophorin II, endoplasmatic reticulum gene involved in Golgi transport),
INTS6 (integrator complex subunit 6, a putative RNA helicase that interacts with RNA polymerase
II), EMP3 (epithelial membrane protein 3, involved in cell proliferation and cell–cell interactions),
JTB (jumping translocation breakpoint, a requirement for cytokinesis during mitosis), and UBE2A
(ubiquitin conjugating enzyme E2 A, an enzyme required for post-replicative DNA damage repair).
Top differentially expressed stable genes in actinomycin D-treated versus untreated samples included
TRIB1 (tribbles pseudokinase 1, encoding an adapter protein involved in protein degradation) and
RPS10P7 (ribosomal protein S10 pseudogene 7) (Figure 2A). In bulk CD8+ TILs, SDHB, MCAT, and
CD27 were the top differentially expressed unstable genes, and IBA57 was one of the top stable genes
(Supplementary Figure S1B). Notably, many unstable CD8+ TIL genes were also differentially unstable
in CD39+CD103+ TRM (Supplementary Table S1 and Supplementary Table S2). To determine the
molecular function of stable transcripts, we classified the top-250 differentially expressed stable genes
in CD39+CD103+ TRM according to the Gene Ontology (GO) molecular function. 71% of stable genes
were appointed to GO functions binding or catalytic activity (Figure 2B and Supplementary Table
S3). Actinomycin D is a chemotherapeutic that inhibits transcription, but it is sometimes also used
as a read-out for platinum-based chemotherapy. We therefore further elaborated on the effect of
actinomycin D on cytotoxic T cell characteristics and hallmark functions by comparing fold-changes
of key immune-related genes. Expression of several TNF ligands and receptors (TNFSF4, TNFSF14,
TNFRSF1A, TNFRSF4, TNFRSF12A, and TNFRSF13C) showed a negative fold change upon actinomycin
D treatment, as did cytokine genes CCL3, CXCL2, CXCL8, and CXCR6 and interleukin (receptor)
genes IL16, IL24, IL15RA, and IL27R (Figure 2C). By contrast, TNFSF9, TNFRSF10A, IL10, IL13, IL21,
and IL22 were relatively stable under actinomycin D. To study the pathway involvement of stable
genes in CD39+CD103+ TRM, we generated a co-functionality network with an integrative tool that
predicts gene functions based on a guilt-by-association (GBA) strategy utilizing >106,000 expression
profiles [29]. The top-250 stable genes (maximum number for this analysis) were analyzed with
default parameters for Biocarta pathways (Figure 2D). We observed two large sub-networks: genes in
sub-network 1 were associated with or assigned to take part in the cell cycle, whereas sub-network
2 contained immunity-related genes. Two smaller sub-networks were associated with complement
and Wnt/VEGF/mTOR signaling (Figure 2D). Interestingly, among the top pathways in the immune
cluster were not only the T cell receptor pathway and cytotoxic T cell/cytotoxicity pathway, but also
the B lymphocyte and NK-T pathways. We have previously hypothesized that CD103+ TIL affect B
cell migration via CXCL13 production, which may in part explain the association with B cell-related
genes/pathways [18].
Although most transcripts decreased after actinomycin D treatment, we also noticed a steady or
even increased number of transcripts for some genes. Thus, we compared median counts of untreated
samples and actinomycin-treated samples (Figure 2E). Many of the significantly enriched transcripts
were mitochondrial genes, such as MT-ND4, MT-CYB, MT-COX1, MT-COX2, and MT-ATP6. Median
expression of EIF1 and EIF4, both associated with translation initiation, also increased upon actinomycin
treatment. Several genes were not expressed in untreated samples but were found in actinomycin
D-treated cells, suggesting de novo synthesis due to transcriptional arrest. These genes included
USP36 (deubiquitinase), MYO6 (actin-based motor molecules), ZNF528 (DNA-binding transcription
activity), AP000648.4 and EMC9 (ER membrane protein). Taken together, we found increased transcript
stability in cell cycle and immunity-related genes, in particular in several TRM-associated genes and
mitochondrial genes.
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2.3. Stimulation with PMA/Ionomycin Induces an Activation-Responsive Genotype in Tumor-Infiltrating
Lymphocytes
To elucidate biological and transcriptional processes in human tumor-associated TRM cells upon
re-activation, we analyzed CD39+CD103+ TRM cells and heterogeneous CD8+ TIL treated with
PMA/ionomycin. Activated CD39+CD103+ TRM differentially expressed 589 genes (Supplementary
Table S4). TWNK (twinkle mtDNA helicase, involved in mitochondrial DNA replication and energy
formation), PLEK (pleckstrin, induces reorganization of the cytoskeleton, involved in lymphocyte
spreading and immune synapse formation), IL21 (interleukin 21) and FOS (FOS proto-oncogene) were
top hits in this analysis (Figure 3A).
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Figure 3. CD39+CD103+ TRM cells differentially upregulate genes associated with immunity, cell cycle,
and the tumor microenvironment. (A) Volcano plot depicting differentially expressed genes (DEseq2)
of CD39+CD103+ TRM cells treated with PMA/ionomycin for four hours versus untreated cells. Each
dot represents a gene with a Benjamini–Hochberg adjusted p-value < 0.05. (B) Venn diagram showing
overlap of differentially expressed genes of PMA/ionomycin-treated CD39+CD103+ TRM cells and
significantly stable genes after actinomycin treat ent. (C) Co-functionality network of the top-250
differentially expressed genes in PMA/ionomycin-treated cells ers s treate 39+CD103+ TRM
cells with default par met rs. Several Biocart t ith z-score > 2 are annotated.
TWNK, PLEK, IL21, and several FOS gene family members (FOSL, FOSB) were also differentially
expressed in CD8+ TIL (Supplementary Figure S1C and Supplementary Table S5), but FOS was not.
FOS is thought to play an important role in signal transduction, cell proliferation, and differentiation
via SMAD3/SMAD4/JUN/FOS complex upon TGF-β stimulation. Indeed, it is very likely that CD103+,
but not CD8+ bulk TIL were exposed to TGF-β in vivo, as we and others have previously shown that
CD103 expression is TGF-β dependent [5,6]. Other differentially expressed genes in activated TRM
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included SPRY1, SPRY2, NR4A2, and NR4A3 (Supplementary Table S3), which are all negative feedback
mechanisms to limit T cell activation. Activated CD8+ TIL top differentially expressed genes were
IL21, RCL1 (RNA terminal phosphate cyclase like 1, involved in rRNA processing), and EGR2 (early
growth response 2, transcription factor with three tandem C2H2-type zinc fingers) (Supplementary
Figure S1C). Several cytokines were differentially expressed in both CD39+CD103+ TRM and CD8+
bulk including IL2, IL10, IL13, IL17A, IL21, and IL22, as were chemokines CCL3, CCL4, and CXCL3
and markers of T cell activation LTA, TNF, TNFSF9, and TNFRSF10A (Figure 3A, Supplementary
Figure S1D, Supplementary Table S4, and Supplementary Table S5). Interestingly, several genes that
were relatively stable upon actinomycin treatment were particularly responsive to PMA/ionomycin
(Figure 3B and Supplementary Figure S1E).
To obtain an idea about the pathways involved in PMA-responsive genes, we entered the top-250
differentially increased genes in PMA-treated CD39+CD103+ TRM in the co-functionality network
analysis as described previously. Within this cohort, we observed two large sub-networks of genes, one
representing several cell cycle pathways and one highly involved in adaptive immunity (Figure 3C).
The overlap in sub-network formation between actinomycin-stable genes and PMA-upregulated
genes may in part be explained by the observed link between genes in these groups (Figure 3B).
A third smaller, but distinctly separate, network of IL13, IL21, ANKAR, CAPS, and IGFALS was
associated with Wnt and VEGF signaling, and are likely associated with environmental cues in
high-grade endometrial cancer. Activated CD39+CD103+ TRM cells thus expressed several classical
and non-classical CD8 T cell cytokines, various markers of T cell activation, and genes associated with
cell cycle and adaptive immunity.
2.4. Cytotoxic T Cells in Endometrial Cancer are Polyfunctional T Cells that can Produce IL-21 and GM-CSF
Activated CD39+CD103+ TRM cells expressed several classical CD8-associated cytokine genes
such as IFNG and IL2, plus several non-CD8 associated cytokines such as IL21 and CSF2. Thus, we
validated these findings by comparing log2-normalized expression between different treatment groups
and Ct-values determined using qPCR for CD39+CD103+ TRM and CD8+ bulk TIL (Figure 4A,B).
Household gene GAPDH was included as an internal reference and control.
CD39+CD103+ TRM and CD8+ TIL expressed some IFNG in resting condition, but minimal to
no TNF, IL2, IL10, and IL13. CD39+CD103+ TRM cells expressed low levels of CSF2 (GM-CSF) in
resting conditions, whereas CD8+ bulk cells did not (Figure 4A). Upon activation, both CD39+CD103+
TRM and CD8+ TIL expressed IFNG, TNF, IL2, IL10, IL13, IL21, and CSF2 mRNA (Figure 4A). The
pattern in qPCR was very similar compared to mRNA expression. The qPCR for IL13 was positive
in water controls, therefore we have not included these and rendered them not determined. The
normalized counts and Ct-values of GAPDH remained stable in different treatment settings in both
populations, indicating the differences observed in cytokine genes are indeed a gene-specific effect of
the PMA/ionomycin and actinomycin D treatments.
We observed a different response to actinomycin D in samples that were treated with both
PMA and actinomycin. Despite pre-incubation with actinomycin, transcription of IFNG, TNF, and
IL2 was barely affected, whereas transcription of IL10 and IL13 strongly decreased. IL21 and CSF2
(GM-CSF) exhibited a somewhat intermediate profile, as combination of actinomycin + PMA lowered
transcription, but did not halt it completely (Figure 4A,B).
To validate our findings on the protein level, we first studied production of CD8+-associated
cytokines IFN-γ, TNF-α, and IL-2 in endometrial cancer cytotoxic TIL. Endometrial cancer digests were
incubated with a protein transport inhibitor containing Brefeldin A with or without PMA/ionomycin.
t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digests showed subsets of
PMA-activated CD8+ TIL produced IFN-γ, TNF-α, and/or IL-2 (Figure 5A), whereas untreated cells
did not (Figure 5A).
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in qPCR was very similar compared to mRNA expression. The qPCR for IL13 was positive in water 
controls, therefore we have not included these and rendered them not determined. The normalized 
counts and Ct-values of GAPDH remained stable in different treatment settings in both populations, 
indicating the differences observed in cytokine genes are indeed a gene-specific effect of the 
PMA/ionomycin and actinomycin D treatments. 
We observed a different response to actinomycin D in samples that were treated with both PMA 
and actinomycin. Despite pre-incubation with actinomycin, transcription of IFNG, TNF, and IL2 was 
barely affected, whereas transcription of IL10 and IL13 strongly decreased. IL21 and CSF2 (GM-CSF) 
exhibited a somewhat intermediate profile, as combination of actinomycin + PMA lowered 
transcription, but did not halt it completely (Figure 4A,B).  
To validate our findings on the protein level, we first studied production of CD8+-associated 
cytokines IFN-γ, TNF-α, and IL-2 in endometrial cancer cytotoxic TIL. Endometrial cancer digests 
were incubated with a protein transport inhibitor containing Brefeldin A with or without 
PMA/ionomycin. t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digests 
Figure 4. CD39+CD103+ TRM and CD8+ TIL robustly express cytokine genes upon stimulation with
PMA/ionomycin. (A) Overview of log2-normalized counts of CD39+CD103+ TRM (red) and CD8+ TIL
(blue). Expression is depicted per treatment condition for GAPDH (household gene) and a series of
cytotoxic T cell cytokines. Bars depict the median. (B) Overview of Ct-values determined using qPCR
of CD39+CD103+ TRM (red) and CD8+ TIL (blue) for the same conditions as depicted in A. qPCR for
IL13 was not determined (N.D.). Bars depict the median. (C) Correlation plots of Ct-values versus
normalized counts of CD39+CD103+ TR (red) and CD8+ TIL (blue). The dashed line represents a
reference correlation of 1 (x = y).
Of PMA-treated TIL, 31.8% (median of 6 samples) produced IFN-γ, TNF-α, IL-2, or a combination
of these (Figure 5B,C), whereas only 3.8% of untreated cells produced any cytokine. In fact, 21.8%
of activated cytokine-producing TIL were p lyfunctional and expressed tw or three of the studied
cytokines (Figure 5C). Our sequencing and qPCR data indicated that TRM and CD8+ TIL might have
a more extensive cytokine epertoire that also include IL-10, IL-13, IL-21, and GM-CSF. To validate
this, we performed a flow cyt metry experiment of PMA/iono ycin-activated and unstimulated
CD8+ TIL from endometrial cancer digests including these markers plus IFN-γ, TNF-α, and IL-2 as an
internal control. Activated CD8+ TIL in endometrial cancer barely produced IL-13 (1.06%), but they
did produce GM-CSF (median 26.08%) and, to a lesser extent, IL-21 (median 8.79%) and very little IL-10
(median 3.7%) (Figure 5D). However, within unstimulated cells, only 2.75% produced GM-CSF, 1.475%
produced IL-21, and 1.16% produced IL-10. Activated cells that produced either GM-CSF or IL-21 were
polyfunctional, as they also produced IFN-y, TNF-α, and IL-2 (Figure 5E). This effect was specific to
tumor-infiltrating lymphocytes, as CD8+ PBMCs did not produce cytokines after stimulation with
PMA/ionomycin, even though they did express mRNA of several cytokines as determined by qPCR
(Supplementary Figure S2A,B). Pretreatment with actinomycin D followed by PMA/ionomycin did
result in transcriptional activation of several genes, albeit the rationale that actinomycin D halts all
transcription. We observed a particular persistence of CCL chemokines, interleukin receptors and some,
but not all, cytokines (Figure 4A,B and Figure 5F). Taken together, cytotoxic TIL are polyfunctional T
cells with an extensive cytokine repertoire that includes production of IL-21 and GM-CSF.
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stained for CD3, CD8, IFN-γ, TNF-α, IL-2, and Zombie Aqua (live/dead stain). (B) Exemplary flow
cytometry image of CD8+ T cells stained for CD3, CD8, IFN-γ, TNF-α, and IL-2. (C) Endometrial
digests stained as described in (B) (n = 6). Percentages of untreated cells (blue) or cells activated
by 4-h incubation with PMA/ionomycin (red) that produce no, one, two, or three of the depicted
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2.5. TRM-Genes and PMA-Responsive Gen s are Associated with Response to Immune Checkpoint Blockade in
Publically Available Sequencing Data
Finally, we determined whether the TRM and PMA-induced gene signature were associated with
response to immune checkpoint inhibition. Therefore, we turned to publicly available sequencing
data of melanoma samples that were taken prior to and upon treatment with immune checkpoint
inhibitor nivolumab [30]. Our hypothesis was that PMA-responsive genes would be particularly
seen in nivolumab-treated, i.e., reactivated, samples. Riaz et al. provided a list of differentially
expressed genes of responders (complete response or partial response) versus non-responders upon
treatment. Interestingly, several of our TRM-signature, stable, or PMA-responsive genes were indeed
reported differentially expressed in responders during treatment, including CD8, CD27, PDCD1, CTL4,
LAG3, IFNG, PLEK, TNFRSF9, TNFRSF10A, CCL3, and CCL4 (Riaz et al. 2017, Supplementary Figure
S3A–C) [30]. We also assessed expression of activation-responsive immune genes TNF, IL21, IL10,
IL13, and CFS2 in the ICB melanoma dataset, and found that IFNG, TNF, and interleukins IL21 and
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IL10 seemed to increase upon treatment in responders (Supplementary Figure S3C), even though they
were not differentially expressed. However, IL21R was differentially expressed (DE) upon treatment
irrespective of response, as were several IL2 receptor genes. Taken together, a number of genes
associated with TRM and PMA signatures were differentially expressed upon treatment with nivolumab
in melanoma patients.
3. Discussion
We have analyzed baseline transcription and transcriptional stability in CD39+CD103+ TRM in
high-grade endometrial cancer and assessed transcriptional and translational responses upon T cell
activation. In this study, we showed that resting CD39+CD103+ TRM cells were transcriptionally active
and expressed a characteristic tissue-resident transcriptional profile comparable to TRM in other tumor
types [31]. We observed expression of ITGAE, ENTPD1, IFNG, TNFRSF9 (CD137), TNFSF10, EGR2,
chemokines CCL3, CCL4, and CCL5, and chemokine receptors CXCR3, CXCR4 and CXCR6. This is in
line with the expression profile of CD103+ tumor-resident T cells in lung cancer, breast cancer, and
ovarian cancer [9,18,19,26,32]. CD39+CD103+ TRM cells are associated with an improved prognosis
in many solid tumors [33] and CD103+ TRM have been linked to response to immune checkpoint
blockade [28,34]. This is further strengthened by the finding that the loss of E-cadherin, the receptor for
the CD103/β7 integrin, inhibits responses to immune checkpoint blockade in melanoma [35]. In spite
of the prognostic effect of CD103+(CD39+) TRM, their phenotype is often considered exhausted and
functionally impaired across tumor types [9,19,26,36]. TRM in our study indeed expressed several
immune checkpoints including HAVCR2, LAG3, CTLA4, and PDCD1. Despite expression of these
inhibitory receptors, CD39+CD103+ TRM cells in this study upregulated markers of T cell activation,
cytolytic activity, and cytokine production upon activation with PMA/ionomycin. In line with this, Abd
Hamid et al. showed that activated TRM cells express superior effector and resident memory profiles
and have higher metabolic activity and mitochondrial capacity compared to non-activated controls [8].
Moreover, activated T cells in our study retained the functional capacity to produce cytokines TNF-α,
IFN-γ, and IL-2. T cells that produce all three of these cytokines (triple-producers) are associated with
superior activity upon rechallenge in viral infections, suggesting this may also hold true in tumor
immunity. A subset of triple-producers also produced IL-21 and GM-CSF ex vivo, but not IL-13 or
IL-10, even though we also observed mRNA expression of IL10 and IL13 in activated TRM. We do not
fully comprehend why IL21 and CSF2 were translated, whereas IL10 and IL13 were not. We speculate
that this could depend on environmental cues within the tumor, and therefore perhaps does not occur
in vitro. Production of IL-21 by cytotoxic T cells is not extensively described, but IL21 mRNA was
found in PD1high CD8+ T cells in a CAR-T solid tumor mouse model [37]. IL-21 promotes effector
functions in naïve CD8+ T cells [38] and is important in CD8+ T cell survival, function, and memory
formation [39]. Indeed, CD8+ T cells incubated with IL-21 showed enhanced tumor regression in an
adoptive cell transfer mouse study [40]. Moreover, IL-21 stimulates B cell differentiation, memory
B cell and plasma cell formation. We hypothesize that this may be an important mode of action for
TRM-produced IL-21, as we have previously shown that CD103+ TRM produce CXCL13 and associate
with B cells and tertiary lymphoid structures in gynecological malignancies [18]. In line with this,
Xiao et al. showed that IL-21 produced by CD8+ T cells promoted IgG production by matched B
cells in vitro [41]. CD39+CD103+ TRM also differentially expressed CSF2 and activated CD8+ TIL
produced GM-CSF ex vivo. GM-CSF, a potent immunostimulatory cytokine, is frequently used as
an adjuvant in cancer vaccination trials and is linked to increased T cell recruitment to the tumor
microenvironment [42].
We observed expression of SPRY1, SPRY2, NR4A2, and NR4A3 in TRM cells, and expression of
these genes increased after T cell activation with PMA. Similarly, expression of SPRY1 and NR4A3 has
been observed in CD103+ TRM in lung cancer [19]. NR4A transcription factors and SPRY are initiated
by NFAT (nuclear factor of activated T cells), and NFAT plays an important role in upregulation of
CD103 on CD8+ T cells. NR4A knockdown in CD8+ CAR-T cells in a solid tumor mouse model
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increased CD8+ T cell effector functions and induced tumor regression [43]. Lack of Sprouty 1 and 2
enhances survival of effector CD8+ T cells [44], and mice with a T cell-selective deletion of Spry1 show
enhanced responses to a tumor vaccine [45]. Reactivation of T cells as mimicked by PMA activation
thus seems to initiate negative feedback mechanisms in T cells, suggesting that (re)activated T cells
are functionally halted by endogenous negative feedback loops. In conclusion, CD39+CD103+ TRM
cells and CD8+ TIL in endometrial cancer are responsive to reactivation and produce both classical
and non-classical cytokines that can influence both T cell and B cell function. Moreover, targeting
activation-induced negative feedback mechanisms that halt TRM activation, such as NR4A, could
perhaps ameliorate responses to immune checkpoint blockade.
We have analyzed transcript stability in CD103+CD39+ TRM by comparing untreated cells to
cells treated with actinomycin D for 30 min followed by four hours of medium incubation prior
to sequencing. Transcript stability prolongs the opportunity for translation, thereby increasing the
bioavailability of the encoded protein. It is relevant to stabilize expression of (synthetic) mRNA
in vitro and in vivo, as exploiting the unique properties of mRNA for therapeutic purposes gains
more attention [46–50]. Von Niessen et al. have described how 3′ untranslated regions (UTRs) can
augment the translation of synthetic mRNA in the context of vaccine antigens to elicit a T cell immune
response [46]. As there are multiple genes whose 3′ UTR regulate mRNA stability, this could be a
potential strategy to control therapeutic gene expression in viral vectors or vaccines. Mitochondrial
transcripts do not possess a 3′ UTR, yet mitochondrial genes were among the most stable transcripts in
our data. The stability of mitochondrial genes has not been elucidated fully but could perhaps be used
in a similar manner as 3′ UTRs to stabilize desired mRNA.
We observed increased expression of several genes in actinomycin D-treated cells compared to
controls, which could be the novo transcription via actinomycin D-insensitive routes. This included
USP36, ZNF528, MYO6, and EMC9. One could hypothesize that the transcriptional halt provided
by actinomycin does not affect all genes evenly, thereby allowing some genes to be less inhibited. It
has been suggested that actinomycin D has preferential binding in CGG-triplet repeat sequences [51].
It could also be that these transcripts were not de novo described, but transcripts were relatively more
abundant due to the decrease in the total number of transcripts after actinomycin D treatment and,
therefore, they were found in this group. However, we have used a high concentration of actinomycin
D that should be sufficient to inhibit all three eukaryotic polymerases [52], and a commonly used
pre-incubation time [53]. Indeed, we observed almost complete inhibition of RNA synthesis in the
actinomycin D monotherapy group, indicating effective inhibition of mRNA transcription.
Interestingly, several actinomycin-stable immune-related genes were particularly responsive
to PMA activation. We hypothesized that the stability of these genes reflects a prolonged but
dormant immune response, rendering these TRM cells primed to rapidly respond once fully activated.
Actinomycin D is a chemotherapeutic that is commonly used in several tumor types, particularly in
sarcomas. In addition, it is sometimes used in in vitro studies to mimic the effect of platinum-based
chemotherapy [54]. Platinum-based compounds act by binding to DNA and inhibiting its replication by
forming cross-links in the DNA that block transcription, eventually resulting in cell death of dividing
cells [55]. Actinomycin D inhibits RNA polymerase function by binding DNA at the transcription
initiation complex, thereby preventing elongation of the RNA. Thus, effects of platinum-based
compounds and actinomycin D on transcription in particular are presumed to be similar. This provides
us with an opportunity to estimate TIL activation in the context of a read-out for adjuvant chemotherapy
in patients with high-risk endometrial cancer. Remarkably, IFNG, TNF, and IL2 were still increased
(IFNG) or even appeared to be de novo transcribed (TNF and IL2) despite the inhibitory effect of
actinomycin D on transcription compared to untreated samples. The hallmark cytokine profile of
cytotoxic CD39+ TRM cells does not seem to be affected by actinomycin D, suggesting that TRM cells
in vivo may preserve cytokine-producing capacities during chemotherapy. Some studies suggest
platinum-based chemotherapy not only induces apoptosis via DNA damage but may also have
immunogenic effects [56]. In addition, our group has recently studied the immune composition prior
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and after neoadjuvant platinum-based chemotherapy and found that the number of tumor-infiltrating
lymphocytes in ovarian cancer was not affected by chemotherapy, although MHC-I expression was
lower [57]. This is in line with findings by others who found CD8+ TIL infiltration to remain stable or
even increase after neoadjuvant platinum-based chemotherapy in ovarian cancer [58–61], implying
that platinum-based chemotherapy may augment a pre-existing immune response. As endometrial
cancer, particularly MSI and POLE-mutant, is generally more immunogenic than ovarian cancer, this
holds promise for patients with (advanced) endometrial cancer. In our study characteristic markers of
TRM cells in EC were responsive to PMA activation and were relatively unaffected by chemotherapy
simulation, implying that a combination strategy of chemotherapy followed by immunotherapy may
be an interesting option for further studies.
We have found that many of the transcriptional processes upon activation were not specific
to CD39+CD103+ TRM but seemed somewhat inherent to CD8+ TIL as a whole population. Upon
examination of the data, we did observe large similarities in the response pattern between TRM and
CD8+ TIL. We have specifically made use of a non-otherwise specified CD8+ TIL population, as we
were interested to study whether observed effects were also visible in a general population as you find
it in a tumor. In line with previous experiments, the fraction of CD39+CD103+ TIL varied per patient,
and therefore provided a representative image of the well-known variation in immune infiltrate in
human tumors. As mentioned previously, high-grade endometrial cancer is a heterogeneous group of
tumors. In this study, we performed sequencing analyses on two high-grade dMMR/MSI endometrioid
tumors and one high-grade p53-mutant pMMR serous tumor. We did not observe general differences
in transcription, and both PMA and actinomycin D responses were consistent between dMMR/MSI
and MSS cases of high-grade EC, although we stress the small size of our group. This suggests that our
findings are of interest to all high-grade EC.
Taken together, our findings showed that CD39+CD103+ TRM cells in high-grade endometrial
cancer are polyfunctional T cells with a reactivation-responsive repertoire, despite their exhausted
phenotype, and these TRM express a variety of immune checkpoints. Secondly, CD39+CD103+
TRM showed increased transcript stability of PMA-responsive and mitochondrial genes, which may
potentiate rapid responses upon TRM cell reactivation in tumors. Thirdly, TRM cells seem to incorporate
activation-induced negative feedback mechanisms that halt TRM activation, and targeting these may
be of interest in optimizing response to immune checkpoint blockade.
4. Materials and Methods
4.1. Tumor Material Preparation
Endometrial cancer digests were obtained from surgical waste material collected in the University
Medical Center Groningen, The Netherlands. Patients had given consent to use surgical waste material
for research purposes. Samples were processed anonymously and assigned a coding number prior to
storage. According to Dutch law no approval from our institutional review board was needed. Of the
material used for sequencing, two tumors were high-grade endometrioid adenocarcinomas with MMR
deficiency (FIGO IA, loss of PMS2, and FIGO IB, loss of MSH2 and MSH6, respectively) and the third
tumor was of high-grade serous p53-mutant adenocarcinoma histology with proficient mismatch repair
proteins, FIGO IIIC2. Tumors were cut into approximately 1cm3, enzymatically digested in RPMI
medium (Gibco, Paisley, UK) with 1 mg/µL collagenase type IV (Gibco Life Technologies, Grand Island,
NY, USA) and 12.6 µg/mL recombinant human DNase (Pulmozyme, Roche, Woerden, the Netherlands)
for 30 min at 37 ◦C or overnight at room temperature. Digests were filtered using 70 µm cell strainers
(Falcon) and enriched for peripheral blood mononuclear cells (PBMCs) using Ficoll-Paque PLUS (GE
Healthcare Life Sciences, Marlborough, MA, USA). Cells were cryopreserved in fetal calf serum (FCS)
with 10% dimethylsulfoxide and stored in liquid nitrogen until further use.
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4.2. Isolation of PBMCs from Healthy Volunteers
Human PBMCs were isolated via Ficoll-Paque density gradient centrifugation (Ficoll-Paque PLUS,
GE Healthcare Life Sciences, Marlborough, MA, USA) from buffy coats of healthy volunteers. Buffy
coats were purchased from Sanquin and all donors gave informed consent (Sanquin Blood Supply,
Groningen, the Netherlands). Isolated PBMCs were cryopreserved in FCS with 10% dimethylsulfoxide
until use.
4.3. CD39+CD103+CD8+ and CD8+ T Cell Sorting
Endometrial cancer tumor digests from three endometrial cancer patients were thawed in RPMI
+ 10% fetal calf serum. Each digest was split four ways; one part remained untreated, one part was
incubated with phorbol myristate acetate (PMA)/ionomycin (1× Cell Stimulation Cocktail, consist of
81 nM PMA and 1.34 µM Ionomycin, eBioscience, 00-4970-93, Waltham, MA, USA) for four hours, one
part was treated with actinomycin D for 4.5 h (5 µg/mL, A1410-2mg, Sigma-Aldrich), and one part was
pre-treated with 30 min of actinomycin D followed by four hours of PMA/ionomycin. All conditions
were incubated at 37 ◦C. Next, samples were washed with PBS 2% FCS and stained with CD103-FITC,
CD39-APC, CD3-PE, and CD8a-BV421 for 30 min at 4 ◦C (Supplementary Table S6). Cells were washed
and filtered using a 35 µm strainer (Falcon). Propidium iodide (1 µg/mL) was used to exclude dead
cells. Per treatment condition, 100 live CD3+CD8+ or 100 live CD3+CD8+CD39+CD103+ cells were
sorted from all digests. Cells were sorted on a Beckman Coulter MoFlo Astrios sorter.
4.4. mRNA Sequencing CD39+CD103+CD8+ and CD8+ Tumor-Infiltrating Lymphocytes
Samples were sorted in 2µL lysis buffer (0.2% Triton X-100 (Sigma-Aldrich) and 2U RNase inhibitor
(Takara)) with 1 µL 10 µM oligo-dT primer and 1 µL 10 mM dNTP mix (Thermo Scientific). After
sorting, the plate was spun down and incubated at 72 ◦C for 3 min. We used a modified SMARTseq2
protocol using custom-made primers (Supplementary Table S7), as described previously [18]. In
brief, SmartScribe reverse transcriptase (Westburg-Clontech) and a template switching oligo (BC-TSO)
were used to generate cDNA. Next, a PCR preamplification step was done with KAPA HiFi HotStart
Ready Mix (Roche Diagnostics) and a custom-made PCR primer. The cDNA samples were purified
using Ampure XP beads (Beckman Coulter) in a ratio of 0.6:1 (Ampure beads: cDNA). Samples were
analyzed on a 2100 Bioanalyzer using a PerkinElmer LabChip GX high-sensitivity DNA chip (Agilent)
and on a Qubit™ 4 Fluorometer (ThermoFisher Scientific) according to the manufacturers’ instructions.
500 pg of each sample were tagmented and N7xx and S5xx index adapters were used for barcoding
according to the Illumina Nextera XT DNA sample preparation kit (Illumina). Thereafter, samples
were purified with Ampure XP beads (ratio 0.6 Ampure: 1 cDNA) and analyzed on a 2100 Bioanalyzer.
Samples were equimolar pooled (4 nM) and samples were sequenced on an Illumina Nextseq500 2500
using 75 bp single-end reads. The obtained mRNA sequencing data was demultiplexed into individual
FASTQ files followed by alignment to the human reference genome hg38 using STAR (version 2.5.2).
4.5. qPCR of mRNA Sequencing Samples and Peripheral Blood CD8+ T Cells
Primers for GAPDH, IL-21, IL-13, IL-10, GMSC-F, TNFα, IFNγ, and IL-2 were ordered from
Invitrogen Europrim (Supplementary Table S8). We performed qPCR in 384 well plates on a Bio-rad
CFX384 Real-Time System. For each qPCR, a 0.5 µL cDNA sample (the same purified cDNA used for
tagmentation) was used. Each reaction consisted of a final concentration of 1× PCR buffer without
Magnesium (Invitrogen), 2.5 mM MgCl2 (Invitrogen), 0.2 mM dNTP mix (Invitrogen), 0.5 U Taq DNA
polymerase (Invitrogen), 0.1 µM of each primer, 1x Evagreen dye (Biotium), and 0.5 µL cDNA.
Int. J. Mol. Sci. 2020, 21, 3770 14 of 18
4.6. Flow Cytometry
Endometrial cancer digests (n = 12) or frozen peripheral blood mononuclear cells were thawed,
washed, and centrifuged. Pellets were resuspended in RPMI with 10% FCS. Half of each sample was
incubated with PMA/ionomycin (eBioscience 1× Cell Stimulation Cocktail) for 4 h at room temperature,
and all samples were incubated with a protein transport inhibitor to enable intracellular cytokine
staining (1:1000, BD GolgiPlug™ Protein Transport Inhibitor, Thermo Fisher Scientific, BD555029,
Waltham, MA, USA). Cells were stained with Zombie Aqua (Zombie Aqua™ Fixable Viability Kit,
#423101, BioLegend) for 15 min, fixed, and permeabilized according to the manufacturer’s protocol
(FIX & PERM™ Cell Permeabilization Kit, #GAS003, ThermoFisher Scientific), followed by incubation
with antibodies for CD3, CD8α, TNF-α, IFN-γ, IL-2 with either IL-21 and IL-13 or IL-10, and GM-CSF
(Supplementary Table S6). Samples were incubated at room temperature for 15 min, washed and
suspended in PBS + 2% FCS. Samples were analyzed on FacsVerse (BD Biosciences) and results were
analyzed with Cytobank premium software (cytobank.org).
4.7. Publically Available Sequencing Data
Fragments per kilobase million (FPKM) values and clinical data of melanoma samples prior and
during Nivolumab treatment, as previously published by Riaz et al., were downloaded from the Gene
Expression Omnibus (GEO) access number GSE91061 [30].
4.8. Statistics
Data were analyzed in R (R software, version 3.6.1) and GraphPad Prism (GraphPad Software Inc.).
Differential expression was determined with DESeq2 package (1.26.0) in R, with a Benjamini–Hochberg
correction. Heatmaps were visualized with the pheatmap package (1.0.12) in R. Guilt-by-association
analysis was performed in Genet-ICA Network (manuscript in preparation) with default parameters
and Biocarta pathways (accessible via http://www.genetica-network.com) [29]. Pathways with a z-score
of >2 were considered relevant. Heatmaps of melanoma data were made with ComplexHeatmap
package (2.2.0) and boxplots were made with ggplot2 package (3.3.0) in R. Throughout the work,
significance was determined as (adjusted) p-value <0.05.
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3770/s1.
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Abbreviations
ACT Actinomycin D
CD Cluster of Differentiation
EC Endometrial cancer
FCS Fetal calf serum
FIGO International Federation of Gynecology and Obstetrics
GM-CSF Granulocyte Macrophage – Colony Stimulating Factor
ICB Immune checkpoint blockade
IL Interleukin
MMR Mismatch repair
- dMMR Mismatch repair deficient




PBMC Peripheral blood mononuclear cells
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